Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious, and other diseases.


News Release

Printer Friendly Version View printer-friendly version
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 15, 2017-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, will report fourth quarter and full-year 2016 financial results after the NASDAQ Global Market closes on Tuesday, February 28, 2017. Subsequently, at 4:30 p.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s chief financial officer, and Bo Cumbo, Sarepta’s senior vice president of global commercial development will host a conference call to discuss fourth quarter and full-year financial results and to provide a corporate update.

The conference call may be accessed by dialing (574) 990-1451 for domestic callers and (844) 534-7313 for international callers. The passcode for the call is 73840094. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2016 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our web site at We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
W2O Group
Brian Reid, 212-257-6725

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.